Alexion bags a blockbuster new approval for its cash cow Soliris. Now what?
Alexion $ALXN has won approval to sell its mainstay therapy Soliris for another batch of patients suffering from an ultra-rare condition — an OK that could well be worth north of a billion dollars.
Last night the FDA came through with an OK for a subset of patients suffering from myasthenia gravis, setting the stage for a new sales effort that Leerink’s Geoffrey Porges believes will rack up $1.2 billion in sales 5 years from now. That’s close to a fifth of the revenue he’s projecting from Soliris — one of the world’s most expensive therapies — for 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
